These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 19236151)
1. Macrophage metalloelastase (MMP-12) as a target for inflammatory respiratory diseases. Lagente V; Le Quement C; Boichot E Expert Opin Ther Targets; 2009 Mar; 13(3):287-95. PubMed ID: 19236151 [TBL] [Abstract][Full Text] [Related]
2. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs? Belvisi MG; Bottomley KM Inflamm Res; 2003 Mar; 52(3):95-100. PubMed ID: 12755372 [TBL] [Abstract][Full Text] [Related]
3. Revisiting matrix metalloproteinase 12: its role in pathophysiology of asthma and related pulmonary diseases. Abd-Elaziz K; Jesenak M; Vasakova M; Diamant Z Curr Opin Pulm Med; 2021 Jan; 27(1):54-60. PubMed ID: 33065600 [TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Gueders MM; Foidart JM; Noel A; Cataldo DD Eur J Pharmacol; 2006 Mar; 533(1-3):133-44. PubMed ID: 16487964 [TBL] [Abstract][Full Text] [Related]
5. Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD). Wu Y; Li J; Wu J; Morgan P; Xu X; Rancati F; Vallese S; Raveglia L; Hotchandani R; Fuller N; Bard J; Cunningham K; Fish S; Krykbaev R; Tam S; Goldman SJ; Williams C; Mansour TS; Saiah E; Sypek J; Li W Bioorg Med Chem Lett; 2012 Jan; 22(1):138-43. PubMed ID: 22153340 [TBL] [Abstract][Full Text] [Related]
7. Pathogenic role of matrix metalloproteases and their inhibitors in asthma and chronic obstructive pulmonary disease and therapeutic relevance of matrix metalloproteases inhibitors. Cataldo DD; Gueders MM; Rocks N; Sounni NE; Evrard B; Bartsch P; Louis R; Noel A; Foidart JM Cell Mol Biol (Noisy-le-grand); 2003 Sep; 49(6):875-84. PubMed ID: 14656045 [TBL] [Abstract][Full Text] [Related]
8. A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? Vandenbroucke RE; Dejonckheere E; Libert C Eur Respir J; 2011 Nov; 38(5):1200-14. PubMed ID: 21659416 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic inhibition of matrix metalloproteinases for the treatment of chronic obstructive pulmonary disease (COPD). Daheshia M Curr Med Res Opin; 2005 Apr; 21(4):587-94. PubMed ID: 15899108 [TBL] [Abstract][Full Text] [Related]
11. Role of matrix metalloproteinases in the development of airway inflammation and remodeling. Lagente V; Manoury B; Nénan S; Le Quément C; Martin-Chouly C; Boichot E Braz J Med Biol Res; 2005 Oct; 38(10):1521-30. PubMed ID: 16172745 [TBL] [Abstract][Full Text] [Related]
12. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Churg A; Wang R; Wang X; Onnervik PO; Thim K; Wright JL Thorax; 2007 Aug; 62(8):706-13. PubMed ID: 17311841 [TBL] [Abstract][Full Text] [Related]
13. Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease. Molet S; Belleguic C; Lena H; Germain N; Bertrand CP; Shapiro SD; Planquois JM; Delaval P; Lagente V Inflamm Res; 2005 Jan; 54(1):31-6. PubMed ID: 15723202 [TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of cigarette smoke-induced chronic obstructive pulmonary disease and therapeutic effects of glucocorticoids and N-acetylcysteine in rats. Xu L; Cai BQ; Zhu YJ Chin Med J (Engl); 2004 Nov; 117(11):1611-9. PubMed ID: 15569474 [TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase 12 silencing: a therapeutic approach to treat pathological lung tissue remodeling? Garbacki N; Di Valentin E; Piette J; Cataldo D; Crahay C; Colige A Pulm Pharmacol Ther; 2009 Aug; 22(4):267-78. PubMed ID: 19327406 [TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Muroski ME; Roycik MD; Newcomer RG; Van den Steen PE; Opdenakker G; Monroe HR; Sahab ZJ; Sang QX Curr Pharm Biotechnol; 2008 Feb; 9(1):34-46. PubMed ID: 18289055 [TBL] [Abstract][Full Text] [Related]
18. Vitamin D deficiency exacerbates COPD-like characteristics in the lungs of cigarette smoke-exposed mice. Heulens N; Korf H; Cielen N; De Smidt E; Maes K; Gysemans C; Verbeken E; Gayan-Ramirez G; Mathieu C; Janssens W Respir Res; 2015 Sep; 16(1):110. PubMed ID: 26376849 [TBL] [Abstract][Full Text] [Related]
19. Relationship between plasma matrix metalloproteinase levels, pulmonary function, bronchodilator response, and emphysema severity. Koo HK; Hong Y; Lim MN; Yim JJ; Kim WJ Int J Chron Obstruct Pulmon Dis; 2016; 11():1129-37. PubMed ID: 27313452 [TBL] [Abstract][Full Text] [Related]
20. Systems pharmacology-based approach for dissecting the active ingredients and potential targets of the Chinese herbal Bufei Jianpi formula for the treatment of COPD. Zhao P; Li J; Li Y; Tian Y; Wang Y; Zheng C Int J Chron Obstruct Pulmon Dis; 2015; 10():2633-56. PubMed ID: 26674991 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]